A study looking at the effect positron emission tomography (PET) scans have on the treatment decisions specialists make in patients with suspected cancer of the pancreas.

A prospective study investigating the impact of the addition of FDG-PET/CT on treatment decisions compared to standard pre-operative work up for patients with suspected pancreatic, peri-ampullary or bile duct malignancies

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12607000604404

Enrollment

Registered

2007-11-23

Start date

2008-01-15

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

In addition to the standard pre-operative investigations you will also undergo a PET scan. Your results will be compared to people who only receive the routine pre-operative investigations, to see if the use of the PET scan changes the treatment plan. A PET scan is a non-invasive nuclear imaging test. In other cancers, particularly lung cancer, this scan can detect the spread of cancer better than other tests. If you have a suspected pancreatic cancer, the usual tests might include a CT (computed tomography) scan, ultrasound, MRI (magnetic resonance imaging) scan and an ERCP (endoscopic retrograde cholangiopancreatography). If a PET scan helps show the extent of the cancer better, your diagnosis will be more accurate and this might spare you unnecessary major surgery.

Interventions

Adding 18 fluorodeoxyglucose positron emission tomography (FDG-PET) which,in other cancers, is better able to pick up cancer spread than other tests are. This scan will be done once at the time of diagnosis and staging.

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

•Suspected or proven localized pancreatic, ampullary or bile duct malignancy on the basis of standard investigations; •= 18 years old; •Deemed suitable, based on tumour stage and medical fitness, to potentially undergo surgery or radiotherapy with curative intent; •Available for follow up for at least 12 months from the date of PET/CT scanning; •Able to provide Informed Consent.

Exclusion criteria

• Claustrophobia; • Uncontrolled diabetes mellitus; • Pregnancy; • Unable to provide informed consent; • Inability to undergo PET/CT study; • Any disease, condition, physical examination finding or clinical laboratory finding which, in the opinion of the investigator, makes the patient inappropriate for the study.

Outcome results